Michael D. Taylor, MD, PhD, is a paediatric neurosurgeon and senior scientist at the University of Toronto affiliated Hospital for Sick Children. His research centres on the molecular genetics of medulloblastoma and ependymoma, two of the most common malignant paediatric brain tumours. He has published over 375 peer-reviewed publications, many in high-impact journals such as Nature, Science, Cell, Cancer Cell, and Lancet Oncology. His publications have been cited over 45,000 times and his findings adopted to improve clinical practice. His group demonstrated that medulloblastoma is comprised of at least four distinct diseases (Journal Clin. Oncol., 2012; Cancer Cell, 2017; Nature, 2017) and that there is clinically significant heterogeneity in metastatic medulloblastomas (Nature, 2012, 2016; Nature Genetics, 2017). His team recently showed that cerebellar tumours are a disorder of early brain development (Nature, 2019), that CAR-T-cells are an effective pre-clinical treatment for Group 3 medulloblastoma and PFA ependymomas (Nature Medicine, 2020) and that PFA ependymomas have a unique metabolic program which leads to a phenotype that appears to be unique among mammalian cells (Cell, 2020).